Table 5 Binary logistic regression analysis of the outcome of the COVID-19 patients who had chronic liver disease with significantly related independent variables

Severity of COVID-19 at admission

1.33

0.36

12.18

< 0.001**

4.77

1.79–7.92

Hepatic encephalopathy at presentation

1.99

0.41

23.39

< 0.001**

7.35

3.28–16.5

High alanine transaminase (U/L)

0.53

0.29

3.21

0.05*

1.69

1.01–2.99

High aspartate transaminase (U/L)

0.69

0.33

4.43

0.04*

1.99

1.05–3.76

Low serum albumin (g/dL)

0.54

0.20

0.83

0.26

1.85

0.74–3.12

High total bilirubin (mg/dL)

0.84

0.36

5.30

0.02*

2.32

1.13–4.75

High direct bilirubin (mg/dL)

1.16

0.52

4.82

0.02*

3.19

1.14–8.98

Low platelet count (× 1000/cmm)

0.45

0.12

1.03

0.72

1.36

0.71–2.39

Length of stay

−0.19

0.10

0.53

0.61

0.63

0.34–1.88

Drug therapy:

 Tocilizumab

−0.16

0.14

0.58

0.13

0.48

0.13–1.12

 Remdesivir

−0.22

0.17

0.73

0.09

0.77

0.55–2.21

Mechanical ventilation

1.93

0.82

5.54

0.02*

6.92

1.38–14.63

Mechanical ventilation duration

0.43

0.11

0.72

0.34

1.46

0.51–4.24

HCV

−0.98

0.43

4.13

0.03*

0.56

0.32–0.83

Treated HCV

−0.86

0.35

3.81

0.04*

0.37

0.21–0.76

Grade C liver cirrhosis

1.24

0.58

3.62

0.04*

2.28

1.01–5.12